Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 6/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL753822 | 0.88 | BRD4 (0.50) | KDM4EALDH1A1SMN1; SMN2POLBHPGD | |
| SCHEMBL5967445 | 0.86 | KDM4E (0.56) | KDM4EALDH1A1SMN1; SMN2POLBHPGD | |
| SCHEMBL13156581 | 0.84 | KDM4E (0.58) | KDM4EALDH1A1SMN1; SMN2POLBHPGD | |
| SCHEMBL27822550 | 0.84 | KDM4E (0.58) | KDM4EALDH1A1SMN1; SMN2POLBHPGD | |
| SCHEMBL8201424 | 0.83 | KDM4E (0.53) | KDM4EALDH1A1SMN1; SMN2POLBHPGD | |
| SCHEMBL8194163 | 0.82 | KDM4E (0.52) | KDM4EALDH1A1SMN1; SMN2POLBHPGD | |
| SCHEMBL8178991 | 0.81 | KDM4E (0.54) | KDM4EALDH1A1SMN1; SMN2POLBHPGD | |
| SCHEMBL26311411 | 0.80 | PARP1 (0.39) | KDM4EALDH1A1SMN1; SMN2POLBHPGD | |
| SCHEMBL295046 | 0.79 | KDM4E (0.58) | KDM4EALDH1A1SMN1; SMN2POLBHPGD | |
| SCHEMBL26311292 | 0.78 | PARP1 (0.38) | KDM4EALDH1A1SMN1; SMN2POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1670760-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | KDM4E 1843/4885ALDH1A1 142/4885SMN1; SMN2 4291/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | KDM4E 1843/4885ALDH1A1 142/4885SMN1; SMN2 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.